You just read:

DARATUMUMAB, a CD38 Monoclonal Antibody Study in Advanced Multiple Myeloma - an Open-Label, Dose Escalation Followed by Open-Label Extension in a Single-Arm Phase I/II Study

News provided by

European Hematology Association

14 Jun, 2013, 07:30 BST